{"id":922282,"date":"2026-10-09T21:20:13","date_gmt":"2026-10-09T21:20:13","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/922282\/"},"modified":"2026-10-09T21:20:13","modified_gmt":"2026-10-09T21:20:13","slug":"novo-nordisk-loses-another-patent-behind-ozempic-and-wegovy-drugs","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/922282\/","title":{"rendered":"Novo Nordisk loses another patent behind Ozempic and Wegovy drugs"},"content":{"rendered":"<p>                        Blockbuster drug<\/p>\n<p class=\"article-header__abstract\">The EPO has reversed its preliminary opinion in the case of another Novo Nordisk patent and revoked it. Generic drug manufacturers could enter the market several years earlier, possibly as early as 2031.<\/p>\n<p class=\"article-header__info\">9 October 2026 by Christina Schulze<\/p>\n<p>                    <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/10\/Wegovy-Ozempic-weight-loss-injection-830x415-Alex-Malt_ADOBE-480x240-c-default.jpeg\" alt=\"Novo Nordisk, semaglutide, weight-loss injections, Wegovy, Ozempic, diabetes\" width=\"480\" height=\"240\" decode=\"async\"\/><\/p>\n<p>                Novo Nordisk loses another patent behind its weight-loss injections Wegovy and Ozempic \u00a9Alex Malt\/ADOBE Stock<\/p>\n<p>                    <img decoding=\"async\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/10\/67556f91a62c44d09833636289e97dc7.gif\" width=\"1\" height=\"1\" border=\"\" class=\"vg-wort-pixel\" style=\"position: absolute;\" loading=\"eager\" data-no-lazy=\"1\" data-skip-lazy=\"1\"\/><img decoding=\"async\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/10\/67556f91a62c44d09833636289e97dc7.gif\" width=\"1\" height=\"1\" border=\"\" class=\"vg-wort-pixel\" style=\"position: absolute;\" loading=\"eager\" data-no-lazy=\"1\" data-skip-lazy=\"1\"\/><\/p>\n<p>Six years\u2019 more or less market exclusivity makes a huge difference to originator manufacturers of blockbuster medicines. And, of course, to generic drug companies too. Consequently, the decision by EPO Board of Appeal 3.3.04 on Thursday afternoon is likely to have far-reaching consequences. Contrary to the assessment in the preliminary opinion, the board revoked Novo Nordisk\u2019s <a href=\"https:\/\/register.epo.org\/application?number=EP17721109\" target=\"_blank\" rel=\"noopener nofollow\">EP 3 448 416<\/a>.<\/p>\n<p>According to JUVE Patent sources, the hearing focused primarily on formal grounds. The discussion centred mainly on comparing the invention with the formulation described in the patent and on the assessment of the publication of a study prior to the patent application.<\/p>\n<p>The revocation of EP 416 is a setback for Novo Nordisk, as there are no divisional applications within this patent family and the patent could have guaranteed protection until 2037. Under the patents that remain valid, market exclusivity for products containing semaglutide could expire as early as 2031.<\/p>\n<p>Potter Clarkson for Novo Nordisk<\/p>\n<p>Novo Nordisk works with various law firms in its <a href=\"https:\/\/www.juve-patent.com\/cases\/epo-revokes-another-novo-nordisk-patent-behind-ozempic-and-wegovy-drugs\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">various patent disputes<\/a> concerning its top-selling blockbuster products. In this case, Antony Proctor, Philip Thomas Potter, and Helen Bartlett of <a href=\"https:\/\/www.juve-patent.com\/firm-rankings\/rankings-uk-2025\/potter-clarkson-uk-2025\/\" target=\"_blank\" rel=\"noopener nofollow\">Potter Clarkson<\/a> led the negotiations.<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.juve-patent.com\/people-and-business\/bonabry-to-merge-with-patent-attorney-firm-hammwittkopp\/attachment\/malte-von-seebach_hammwittkopp-400x300\/\" rel=\"nofollow noopener\" target=\"_blank\"><img fetchpriority=\"high\" decoding=\"async\" width=\"300\" height=\"225\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/10\/Malte-von-Seebach_HammWittkopp-400x300-1-300x225.jpg\" class=\"attachment-medium size-medium\" alt=\"Malte von Seebach\" aria-describedby=\"gallery-1-72193\"  \/><\/a><\/p>\n<p>\t\t\t\tMalte von Seebach<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.juve-patent.com\/cases\/epo-revokes-another-novo-nordisk-patent-behind-ozempic-and-wegovy-drugs\/attachment\/marco-fachini-400x300\/\" rel=\"nofollow noopener\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"225\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/10\/Marco-Fachini-400x300-1-300x225.jpg\" class=\"attachment-medium size-medium\" alt=\"Marco Fachini\" aria-describedby=\"gallery-1-60787\"  \/><\/a><\/p>\n<p>\t\t\t\tMarco Fachini<br \/>\n\t\t\t\t<br style=\"clear: both\"\/><\/p>\n<p>Malte von Seebach of <a href=\"https:\/\/www.juve-patent.com\/firm-rankings\/rankings-germany-2025\/hammwittkopp-germany-2025\/\" target=\"_blank\" rel=\"noopener nofollow\">Hamm&amp;Wittkopp<\/a> led the team of opponents on behalf of client Stada. Marco Fachini of <a href=\"https:\/\/www.juve-patent.com\/firm-rankings\/rankings-germany-2025\/kraus-lederer-germany-2025\/\" target=\"_blank\" rel=\"noopener nofollow\">Kraus &amp; Lederer<\/a> represented Teva.<\/p>\n<p>Veronica M\u00fcller of <a href=\"https:\/\/www.juve-patent.com\/firm-rankings\/rankings-germany-2025\/ter-meer-steinmeister-partner-germany-2025\/\" target=\"_blank\" rel=\"noopener nofollow\">Ter Meer Steinmeister &amp; Partner<\/a> represented Generics. Sandoz, as the opponent, relied on Paul Brookes of <a href=\"https:\/\/www.juve-patent.com\/firm-rankings\/rankings-uk-2025\/patent-filing-uk-2025\/#elkington-fife\" target=\"_blank\" rel=\"noopener nofollow\">Elkington + Fife<\/a>. Adalvo worked with Emma Battell of Brand Murray Fuller. Christoph Sch\u00f6n and Rudolf Sch\u00f6n of Dr Schoen, Neymeyr &amp; Partner Patentanw\u00e4lte acted as frontmen.<\/p>\n","protected":false},"excerpt":{"rendered":"Blockbuster drug The EPO has reversed its preliminary opinion in the case of another Novo Nordisk patent and&hellip;\n","protected":false},"author":2,"featured_media":922283,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[64,63,137,490],"class_list":["post-922282","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-au","tag-australia","tag-health","tag-medication"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/922282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=922282"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/922282\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/922283"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=922282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=922282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=922282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}